IP Library Granted Patent US 7,790,446
Granted Patent B2
US 7,790,446 · App. 11/351,809 · Granted Sep 7, 2010

Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products

Assignee: Kosagen Cell Factory Oü
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,446
App. No.
11/351,809
Granted
Sep 7, 2010
Kind
B2
Abstract

This disclosure shows that the BPV-1 E2 protein-dependent minichromosome maintenance element (MME) comprised of E2 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). MME dependent plasmids are lost with the frequency of 6% per generation. Significantly long stable maintenance replication can also be provided without selection pressure. We also demonstrate that PyV core origin maintenance function/replication activation could be provided by Epstein-Barr virus Family of repeats and EBNA1 protein. The maintenance of the Polyomavirus core origin plasmid was characterized by 13% loss of the plasmid during one cell generation in the case of EBV FR harboring plasmids. Our data clearly indicate that maintenance functions from different viruses can provide segregation/partitioning function to different heterologous origins in variety of cells and can be used in expression of gene products.

Claims (26)

1. An expression system to provide extended episomal replication of hybrid plasmids in eukaryotic cell lines, said system comprising:

a) a vector having a mouse polyoma virus core origin obtained from a complete polyoma virus origin by removing enhancer element; a papillomavirus minichromosomal maintenance element (MME), said MME being a Bovine papillomavirus (BPV) MME and containing at least 5 E2-binding sites, said E2-binding sites being SEQ ID NO:9; an optional selection marker; and a gene of interest operably linked within an expression cassette expressing the gene in a eukaryotic cell; and

b) a compatible cell line, wherein the vector is expressed, said cell line constitutively expressing BPV-E2 protein and mouse polyomavirus (PyV) LT protein either in presence or in absence of selective pressure.

2. The system according to claim 1 , wherein the expression of BPV E2 and PyV LT in the cell line is provided by a vector or vectors comprising coding sequences of BPV E2 and PyV LT proteins.

3. The system according to claim 1 , wherein the core origin is SEQ ID NO: 2.

4. The system according to claim 1 , wherein the cell line is of mouse, hamster or human origin.

5. The system according to claim 4 , wherein the cell line is selected from the group consisting of Chinese hamster ovary cells (CHO), mouse COP5 cell line and human cell line 293.

6. The expression system of claim 1 , wherein the MME contains 10 E2-binding sites of SEQ ID NO:9.

7. An expression system to provide extended episomal replication of hybrid plasmids in eukaryotic cell lines, said system comprising:

a) a first vector having a mouse polyoma virus core origin obtained from a complete polyoma virus origin by removing enhancer element; a papillomavirus MME, said MME being a BPV MME and containing at least 5 E2-binding sites being SEQ ID NO:9; an optional selection marker; and first gene of interest operably linked within eukaryotic expression cassette expressing the gene in a eukaryotic cell;

b) a second vector having a mouse polyoma virus core origin obtained from a complete polyoma virus origin by removing enhancer element, an FR element of EBV, an optional selection marker, and a second gene of interest operably linked within an expression cassette expressing the gene in a eukaryotic cell; and

c) a compatible cell line wherein the vectors are expressed, said cell line constitutively expressing BPV E2 protein, EBV EBNA1 protein and PyV LT protein either in presence or in absence of selective pressure.

8. The system according to claim 7 , wherein the expression of BPV E2, EBV EBNA1 and PyV LT in the cell line is provided by a vector or vectors comprising coding sequences of BPV E2, EBV EBNA1 and PyV LT proteins.

9. The system according to claim 7 , wherein the FR element comprises at least 16 EBNA 1 binding sites.

10. The system according to claim 9 , wherein the EBNA1 binding sites are selected from the group consisting of SEQ ID NO:s 10,12 and 13.

11. The system according to claim 7 , wherein the core origin is SEQ ID NO: 2.

12. The system according to claim 7 , wherein the cell line is of mouse, hamster or human origin.

13. The system according to claim 12 , wherein the cell line is selected from the group consisting of CHO, COP5 and human cell line 293.

14. The system according to claim 7 , wherein the system additionally includes:

a third vector, said third vector comprising a minimum core origin of a papillomavirus, a papillomavirus MME and, a third gene of interest operably linked within an expression cassette expressing the gene in a eukaryotic cell; and

the cell line constitutively expresses BPV E2 protein, BPV E1 protein, EBV EBNA1 protein and Py LT protein.

15. The system according to claim 14 , wherein the expression of BPV E2, BPV E1, EBV EBNA1 and PyV LT in the cell line is provided by a vector or vectors comprising coding sequences of BPV E1, BPV E2, EBV EBNA2 and PyV LT proteins.

16. The system according to claim 15 , wherein the system additionally includes a fourth vector, said fourth vector comprising:

a minimum core origin of a papillomavirus,

an EBV FR-element; and

a fourth gene of interest operably linked within an expression cassette regions expressing the gene in a eukaryotic cell.

Assignments (3)
CHANGE OF NAME Recorded Jun 23, 2009
From: QUATTROMED CELL FACTORY OU
To: ICOSAGEN CELL FACTORY OU
Reel/Frame 022870/0895 →
CHANGE OF NAME Recorded Jun 23, 2009
From: OU, RAKUVABRIK
To: QUATTROMED CELL FACTORY OU
Reel/Frame 022872/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2006
From: TARTU, UNIVERSITY OF
To: RAKUVABRIK LTD
Reel/Frame 018270/0991 →
Continuity (2)
Provisional Application 6065239000 · Feb 11, 2005
Related Publication 20060183230A1 · Aug 17, 2006